trending Market Intelligence /marketintelligence/en/news-insights/trending/T5oNZFdfFjZtKEraXyQSdw2 content esgSubNav
In This List

Novo Nordisk diabetes drug wins EU approval for expanded use in children

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Novo Nordisk diabetes drug wins EU approval for expanded use in children

The European Commission approved the expanded use of Novo Nordisk A/S' diabetes medicine Fiasp to include adolescents and children aged 1 year and older.

The Denmark-based pharmaceutical giant's drug Fiasp — a fast-acting insulin — is already approved for managing diabetes in adults.